{"schema_version":"1.0","type":"article","title":"浩鼎授權諾華，ADC合約拆解","url":"https://drugnews.com.tw/articles/2026-11-15-obi-novartis-adc-platform.html","markdown_url":"https://drugnews.com.tw/articles/2026-11-15-obi-novartis-adc-platform.md","lang":"zh-Hant","date":"2026-11-15","publish_at":"2026-11-15T08:00:00+08:00","updated_at":"2026-11-15","category":"商業分析系列","topic":"BD / 授權","tags":["浩鼎","諾華","ADC","平台授權"],"summary":"浩鼎與諾華的平台合作約定3,000萬美元簽約金，總潛在價值逾20億美元；拆解酬載排他範圍、條件款、研究分工與未揭露條款。","key_points":["3,000萬美元是已約定簽約金，未確認已收；總潛在價值逾20億美元。","獨家範圍以特定諾華酬載類別描述，是否另限靶點未揭露。","選擇權價格、研究費、保留權利與終止條款未揭露。"],"facts":[],"sections":["01｜3,000萬美元與逾20億，分屬兩種承諾","02｜酬載界定範圍，平台技術負責接合","03｜同類平台交易，要連工作與選擇權一起比","04｜台灣平台合作，資源與保留空間都要算","05｜公告沒回答，投資人可以問的五個問題","參考資料"],"references":[{"title":"[2] 2025年合併財務報告，頁8、10、13","source":"OBI Pharma","date":"2026-03-09","url":"https://www.obipharma.com/investor-overview/financial-report/"},{"title":"[5] Technology Platform","source":"OBI Pharma","date":"","url":"https://www.obipharma.com/what-we-do/technology-platform/"},{"title":"[6] Pipeline Overview","source":"OBI Pharma","date":"","url":"https://www.obipharma.com/what-we-do/pipeline-overview/"},{"title":"[11] Chugai and Araris enter license agreement","source":"Chugai","date":"2026-02-10","url":"https://www.chugai-pharm.co.jp/english/news/detail/20260210173000_1227.html"},{"title":"[12] Global collaboration with Genentech on DUPAC","source":"DualityBio","date":"2026-08-28","url":"https://en.dualitybiologics.com/news/614.html"},{"title":"[13] OBI decided to terminate OBI-822 Phase 3 study","source":"OBI Pharma","date":"2025-04-23","url":"https://www.obipharma.com/announcement/obi-decided-to-terminate-obi-822-phase-3-study-based-on-dsmbs-recommendation-and-to-redirect-resources-towards-adcs-development/"},{"title":"[16] 台灣浩鼎與諾華簽署合作暨授權協議，瀏覽器完整正文","source":"台灣浩鼎","date":"2026-11-13","url":"https://www.obipharma.com/zh-hant/news/signs-collaboration-and-license-agreement-with-novartis/"},{"title":"[17] 新臺幣／美元銀行間收盤匯率32.838","source":"中央銀行","date":"2026-11-13","url":"https://www.cbc.gov.tw/tw/mp-1.html"},{"title":"[18] 115年第3季合併資產負債表、綜合損益表及現金流量表","source":"MOPS／4174","date":"","url":"https://mopsov.twse.com.tw/mops/web/t164sb03"},{"title":"[19] 公告本公司召開重大訊息記者會新聞稿內容，序號3、17:17:30","source":"MOPS／4174","date":"2026-11-13","url":"https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=true&step=2&off=1&TYPEK=otc&co_id=4174&spoke_date=20261113&spoke_time=171730&seq_no=3"},{"title":"[20] Collaboration and License Agreement with Novartis，英文完整正文","source":"OBI Pharma","date":"2026-11-13","url":"https://www.obipharma.com/news/signs-collaboration-and-license-agreement-with-novartis/"},{"title":"[21] Boehringer Ingelheim broadens oncology portfolio，Synaffix公司原始發布稿","source":"Synaffix B.V.／PR Newswire","date":"2025-01-09","url":"https://www.prnewswire.com/news-releases/boehringer-ingelheim-broadens-oncology-portfolio-with-license-for-synaffixs-adc-technology-302346940.html"},{"title":"本文為產業與公司分析，不構成投資或醫療建議。","source":"","date":"","url":""}],"images":[{"alt":"圖1｜簽約金與條件款沿不同進度支付","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform/figure-01.png"},{"alt":"圖2｜醣基定點偶聯讓酬載接上抗體","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform/figure-02.png"},{"alt":"圖3｜同類交易的前期款與條件款口徑不同","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform/figure-03.png"},{"alt":"圖4｜自研管線與平台合作並行","url":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform/figure-04.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/obi-novartis-adc-platform/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-11-15）。浩鼎授權諾華，ADC合約拆解。https://drugnews.com.tw/articles/2026-11-15-obi-novartis-adc-platform.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/","faq":[{"q":"「3,000萬美元是已約定簽約金，未確認已收」有哪些關鍵變化？","a":"3,000萬美元是已約定簽約金，未確認已收；總潛在價值逾20億美元。"},{"q":"「獨家範圍以特定諾華酬載類別描述，是否另限靶點未揭露」有哪些關鍵變化？","a":"獨家範圍以特定諾華酬載類別描述，是否另限靶點未揭露。"},{"q":"「選擇權價格、研究費、保留權利與終止條款未揭露」有哪些關鍵變化？","a":"選擇權價格、研究費、保留權利與終止條款未揭露。"}]}